Processa Pharmaceuticals, Inc. PCSA
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is an immunology/inflammation drug developer. Its lead program, VT-7208, is in Phase 1 for Food allergy, chronic spontaneous urticaria, relapsing multiple sclerosis. Its next catalyst on record is VT-7208: Initiate Phase 2 studies in food allergy and CSU (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VT-7208 — Initiate Phase 2 studies in food allergy and CSU (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VT-7208 (BTK inhibitor) | Food allergy / CSU / RMS | small molecule | Phase 2 PoC food allergy data 2027-H2; CSU 2028-H1; RMS 2028-H2 |
| PCS11T (NGC-Iri) | Solid tumors | small molecule | — |
Recent results and decisions
- Jul 29, 2026n/a Processa acquired Vidya Therapeutics (BTK inhibitor VT-7208, Phase 1 complete) in a stock-for-stock deal with a concurrent ~$200M private placement; runway into 2H 2029.
Processa Pharmaceuticals, Inc. (Processa) (Nasdaq: PCSA) today announced it has acquired Vidya Therapeutics, Inc. (Vidya), a clinical-stage biotechnology company developing VT-7208, a Bruton’s tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.